Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study

Molecular Psychiatry

Volumn 19, Issue 9, 2014, Pages 1044-1051

  Doraiswamy, P Murali ^a   Sperling, R A ^b   Johnson, K ^b   Reiman, Eric M ^c   Wong, T Z ^a   Sabbagh, M N ^d   Sadowsky, Carl H ^e,z   Fleisher, A S ^c,f   Carpenter, A ^g   Joshi, A D ^g   Lu, M ^g   Grundman, M ^f,h   Mintun, M A ^g   Skovronsky, D M ^g   Pontecorvo, M J ^g   Duara, Ranjan ⁱ   Sabbagh, Marwan ^d   Ahern, Geoffrey Lawrence ^j   Holub, Richard F ^k   Farmer, Mildred V ^l   Safirstein, Beth Emmie ^m   Alva, Gustavo ⁿ   Longmire, Crystal F ^o   Jewell, George ^p   Johnson, Keith A ^b   Korn, Ron ^q   Wendt, Jeanette K ^r   Wong, Dean ^s   Coleman, R Edward ^a   Devous, Michael ^t   Jennings, Danna ^u   Weiner, Michael W ^v   Murphy, Cynthia A ^w   Kovnat, Karel D ^x   Williamson, Jeff D ^y   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BANNER ALZHEIMER S INSTITUTE   (United States)

^d SUN HEALTH RESEARCH INSTITUTE   (United States)

^e NOVA SOUTHEASTERN UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g AVID RADIOPHARMACEUTICALS   (United States)

^h Global R and D Partners   (United States)

ⁱ MOUNT SINAI MEDICAL CENTER   (United States)

^j UNIVERSITY OF ARIZONA   (United States)

^k Neurologic Associates Albany   (United States)

^l Meridien Research   (United States)

^m MD Clinical   (United States)

ⁿ ATP Clinical Research   (United States)

^o MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^p Dayton Center for Neurological Disorders   (United States)

^q Scottsdale Medical Imaging   (United States)

^r Northwest Neurospecialists   (United States)

^s DEPARTMENT OF PATHOLOGY   (United States)

^t UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^u Molecular Neuroimaging   (United States)

^v VETERANS AFFAIRS MEDICAL CENTER   (United States)

^w Memory Clinic   (United States)

^x Adler Institute for Advanced Imaging   (United States)

^y WAKE FOREST SCHOOL OF MEDICINE   (United States)

^z Palm Beach Neurology   (United States)

more..

Author keywords

alzheimer's disease; amyloid; cognitive decline; florbetapir; MCI; PET

Indexed keywords

AMYLOID BETA PROTEIN; DONEPEZIL; FLORBETAPIR F 18; GALANTAMINE; MEMANTINE; RIVASTIGMINE; ANILINE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; NOOTROPIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ASSESSMENT OF HUMANS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIGIT SYMBOL SUBSTITUTION TEST; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; VERBAL FLUENCY TEST; VERY ELDERLY; WECHSLER MEMORY SCALE; BRAIN; CLINICAL TRIAL; DIAGNOSTIC USE; DISEASE COURSE; LONGITUDINAL STUDY; METABOLISM; NEUROPSYCHOLOGICAL TEST; SCINTISCANNING;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BRAIN; DISEASE PROGRESSION; ETHYLENE GLYCOLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS;

EID: 84905557091     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2014.9     Document Type: Article

References (42)

1. Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. Jan 2011; 76: 280-286.
2. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-279.
3. Weiner MW, Aisen PS, Jack CR Jr., Jagust WJ, Trojanowski JQ, Shaw L et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 2010; 6: 202-211 e207.
4. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997; 18(4 Suppl): S1-S2.
5. Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM et al. Florbetapir PET analysis of amyloid-beta deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol 2012; 11: 1057-1065.
6. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367: 795-804.
7. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-292.
8. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-319.
9. Nordberg A, Rinne JO, Kadir A, Langstrom B. The use of PET in Alzheimer disease. Nat Rev Neurol 2010; 6: 78-87.
10. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009; 66: 1469-1475.
11. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren K et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009; 73: 754-760.
12. Jack CR Jr., Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G et al. Brain betaamyloid measures and magnetic resonance imaging atrophy both predict timeto- progression from mild cognitive impairment to Alzheimer's disease. Brain 2010; 133: 3336-3348.
13. Koivunen J, Scheinin N, Virta JR, Weigand SD, Senjem ML, Zeng G et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology 2011; 76: 1085-1090.
14. Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011; 69: 181-192.
15. Villemagne VL, Pike KE, Darby D et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 2008; 46: 1688-1697.
16. Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009; 65: 557-568.
17. Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol 2009; 66: 1476-1481.
18. Resnick SM, Sojkova J, Zhou Y, Zhou Y, An Y, Ye W et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 2010; 74: 807-815.
19. Lim YY, Ellis KA, Pietrzak RH, Ames D, Darby D, Harrington K et al. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology 2012; 79: 1645-1652.
20. Pontecorvo MJ, Mintun MA. PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease. Alzheimers Res Ther 2011; 3: 11.
21. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med 2009; 50: 1887-1894.
22. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011; 305: 275-283.
23. Barthel H, Gertz HJ, Dresel S et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011; 10: 424-435.
24. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008; 7: 129-135.
25. Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 2013; 9(5 Suppl): S72-S83.
26. Sperling RA, Johnson KA, Doraiswamy PM, Reiman EM, Fleisher AS, Sabbagh MN et al. Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging 2013; 34: 822-831.
27. Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD et al. Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012; 79: 1636-1644.
28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
29. Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 2011; 68: 1404-1411.
30. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31: 1275-1283.
31. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A. 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50: 136-145.
32. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269-2276.
33. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-638.
34. Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG et al. Clinical core of the Alzheimer's disease neuroimaging initiative: progress and plans. Alzheimers Dement 2010; 6: 239-246.
35. Ramanan VK, Risacher SL, Nho K, Kim S, Swaminathan S, Shen L et al. APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genomewide association study. Mol Psychiatry advance online publication, 19 February 2013; doi:10.1038/mp.2013.19.
36. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC et al. The Alzheimer's disease neuroimaging Initiative: a review of papers published since its inception.. Alzheimers Dement 2012; 8(1 Suppl): S1-68.
37. Wu L, Rowley J, Mohades S, Leuzy A, Dauar MT, Shin M et al. Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. PLoS ONE 2012; 7: e47905.
38. Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012; 72: 578-586.
39. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2009; 106: 6820-6825.
40. Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2013; 40: 104-114.
41. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol 2012; 11: 669-678.
42. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CRJr, Kawas CH et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-269.